Operating profit growth (quarterly)

Total operating profit -75% and Total EPS -69% driven by higher impairments, primarily related to camlipixant of £1.3 billion, and higher CCL charges, partly offset by Core operating profit growth and higher divestment income

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4

Copy

MLA

GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2026, https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4.

Copy

Chicago

GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4.

Copy

BibTeX

@misc{gsk2026operatingfshyq4, author = {{GSK}}, title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: quarterly. This page is permanently addressable at statorigin.org/stat/stat_1DN19V4QD824M3FEKW6YFSHYQ4.